Is AOD-9604 Legal in Oregon?

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide derived from the C-terminal fragment (amino acids 177-191) of human growth hormone. Researchers originally studied it for its lipolytic properties without the insulin-resistance effects of full-length growth hormone. The molecule stimulates beta-3 adrenergic receptors and has been shown in animal models to reduce adipose tissue without raising IGF-1 levels.

Clinical Trial Background

The compound was developed by Metabolic Pharmaceuticals Ltd., which ran a Phase IIb/III trial under the name Tyr-hGH Frag 176-191 (also marketed under the Investigational New Drug designation AOD9604). That Australian trial enrolled 300 obese adults and showed modest but statistically significant weight reduction over 12 weeks at the 1 mg oral dose, though the effect did not replicate consistently across dose arms [1].

The FDA never approved AOD-9604 as a finished drug product. Metabolic Pharmaceuticals ceased pursuing a New Drug Application (NDA), which is why AOD-9604 today exists only as a compounded or research-grade substance rather than a dispensed pharmaceutical.

Why the Science Matters for Legal Status

Regulatory agencies evaluate a substance's legal standing in part based on whether it has an approved NDA or Abbreviated NDA (ANDA). Because AOD-9604 has neither, it cannot be marketed as a drug in the United States through standard commercial channels [2]. That single fact shapes every layer of the legal framework that Oregon patients and providers must understand.

Federal Legal Framework: The FDA Compounding Rules

The starting point for any analysis of peptide legality in the United States is federal law, specifically the Drug Quality and Security Act of 2013 (DQSA), which amended Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [3].

Section 503A: Patient-Specific Compounding

Under 503A, a state-licensed pharmacy may compound a drug preparation for an identified individual patient based on a valid prescription from a licensed practitioner. The pharmacy must use bulk drug substances that either appear on the FDA's 503A bulk drug substances list (the "positive list") or are components of FDA-approved drugs, or are on a list of bulk substances under evaluation [4].

AOD-9604 is not on the 503A positive list. It is, however, being evaluated. Until the FDA takes a final action to either include or exclude it from that list, pharmacies operating in good faith under a physician prescription occupy a genuinely uncertain but not clearly prohibited space.

The FDA's own guidance document on bulk drug substances states that while a substance is under evaluation, compounding may continue at the pharmacist's and prescriber's risk pending a final determination [4]. That measured language is the closest thing to official permission that currently exists.

Section 503B: Outsourcing Facilities

503B outsourcing facilities are allowed to produce compounded drugs at scale without patient-specific prescriptions, but only using substances on the FDA's 503B bulk drug substances list. AOD-9604 does not appear on that approved list [5]. As a result, 503B facilities cannot legally compound AOD-9604 for commercial distribution in Oregon or any other state.

This distinction matters enormously for patients who receive peptide preparations from large compounding operations: if the product is AOD-9604 and it came from a 503B facility, there is a meaningful regulatory compliance question about that supply chain.

The FDA's Broader Position on Peptides

In 2023 and 2024, the FDA took increasingly firm positions on compounded peptides. The agency's February 2024 guidance on bulk drug substances under 503A clarified that it would move to finalize the status of several peptides, including some that were previously tolerated under enforcement discretion [6]. AOD-9604 had not been formally excluded as of July 2025, but prescribers should monitor updates from the FDA's pharmacy compounding page regularly because the regulatory environment is shifting.

The FDA has stated: "Outsourcing facilities may only compound drug products using bulk drug substances that appear on the FDA's list of bulk drug substances that can be used in compounding" [5]. That unambiguous statement from the agency's own 503B guidance forecloses the large-scale route.

Oregon State Legal Framework

Oregon's rules do not add a separate state-level prohibition on AOD-9604, but they do layer state-specific licensing and practice requirements on top of the federal floor.

Oregon Board of Pharmacy

The Oregon Board of Pharmacy (OBP) licenses pharmacies and pharmacists operating in the state and enforces the Oregon Pharmacy Practice Act (ORS Chapter 689). Oregon adopted rules that align with USP Chapter 795 (non-sterile compounding) and USP Chapter 797 (sterile compounding), the same standards the FDA references for 503A pharmacies [7].

Under OBP rules, a compounding pharmacy in Oregon may prepare a patient-specific preparation if:

• A valid prescription from a licensed Oregon practitioner exists.
• The preparation is not essentially a copy of a commercially available drug.
• The bulk substances used are pharmaceutical-grade and from an FDA-registered supplier.

AOD-9604 meets the "not a copy of a commercially available drug" criterion easily, because no FDA-approved version exists. The question of pharmaceutical-grade supply is where providers and pharmacies must exercise due diligence.

Oregon Medical Practice Act

The Oregon Medical Practice Act (ORS Chapter 677) governs what licensed physicians, nurse practitioners, and physician assistants may prescribe. Oregon law does not maintain a separate list of prohibited prescription substances beyond those controlled under the federal Controlled Substances Act (CSA) and Oregon's own controlled substances schedules [8].

AOD-9604 appears on neither the federal CSA schedules nor the Oregon controlled substances schedules as of July 2025 [9]. A licensed Oregon prescriber therefore has the legal authority to write a prescription for a compounded AOD-9604 preparation, provided that prescription is for a legitimate medical purpose and is based on a valid patient-provider relationship.

The HealthRX Medical Team applies a three-gate framework before any AOD-9604 prescription is issued in states like Oregon:

1. Gate 1: FDA bulk substance status confirmed as not finally excluded. If the FDA has finalized exclusion of AOD-9604 from the 503A list, compounding is no longer defensible.
2. Gate 2: Pharmacy is 503A-licensed in Oregon (not a 503B outsourcing facility operating under a different legal standard).
3. Gate 3: A documented clinical indication exists in the patient chart, such as obesity (BMI >30) or overweight (BMI 27-30) with a metabolic comorbidity, supported by labs and a treatment plan.

All three gates must be open for a prescription to proceed within our clinical protocols.

Is AOD-9604 a Controlled Substance in Oregon?

No. AOD-9604 is not scheduled under the federal Controlled Substances Act, and it does not appear on Oregon's controlled substances schedule (OAR 855-080) [8][9]. This means possession of AOD-9604 prescribed by a licensed Oregon provider and dispensed by a licensed Oregon 503A pharmacy does not carry criminal exposure under drug-scheduling laws.

The distinction between "not a controlled substance" and "fully legal to sell" is one that trips up patients and even some providers. Not being scheduled means law enforcement does not treat possession as a narcotics violation. It does not mean AOD-9604 can be sold over the counter, marketed as a supplement, or purchased from a research chemical vendor without regulatory risk.

How to Get AOD-9604 in Oregon: A Step-by-Step Pathway

Step 1: Establish a Relationship with a Licensed Prescriber

A prescription is required. Telehealth platforms with Oregon-licensed prescribers, or in-person visits with a physician, nurse practitioner, or PA who manages metabolic health, are both valid pathways. The prescriber must conduct a clinical evaluation, not simply receive a patient request.

Step 2: Clinical Evaluation and Documentation

The prescriber should document the clinical rationale. AOD-9604 is typically discussed in the context of weight management in adults who have not achieved adequate results with lifestyle modification alone. Labs that provide useful baseline data include fasting insulin, HbA1c, lipid panel, and IGF-1 levels. A baseline IGF-1 is particularly relevant given AOD-9604's growth hormone lineage, even though the peptide is designed to spare IGF-1 elevation.

Step 3: Prescription to a 503A Oregon-Licensed Compounding Pharmacy

The prescription must go to a pharmacy that holds an Oregon compounding license and operates under 503A. The pharmacy should use USP-grade AOD-9604 sourced from an FDA-registered bulk drug supplier. Patients should ask their pharmacy to confirm the certificate of analysis (COA) from the supplier.

Standard compounded doses used in clinical practice range from 250 mcg to 500 mcg subcutaneous injection daily, typically administered in the morning before eating. Some protocols use oral or intranasal formulations, though the bioavailability data for non-injection routes is limited [1].

Step 4: Monitoring

Follow-up at four to eight weeks is standard. The prescriber should assess weight, body composition if possible, and watch for any adverse effects. Known adverse events from the Phase II trials were mild and included injection-site reactions and transient headache [1]. IGF-1 should be rechecked at 12 weeks if there is any clinical concern.

What Patients Cannot Legally Do in Oregon

Buy AOD-9604 Online Without a Prescription

Vendors selling AOD-9604 labeled "for research use only" operate in a regulatory space the FDA has described as misbranded or adulterated product. Purchasing from those vendors does not create a legal route for human use. The FDA has issued warning letters to research chemical suppliers selling peptides for human use without going through the NDA or compounding pathway [6].

Use 503B-Sourced AOD-9604

As noted above, 503B outsourcing facilities cannot compound AOD-9604 under current federal rules [5]. If a pharmacy or clinic cannot clearly state its 503A status, patients should verify before using the product.

Obtain AOD-9604 as a Dietary Supplement

The Dietary Supplement Health and Education Act of 1994 (DSHEA) does not cover synthetic peptides that are investigated as drugs [10]. AOD-9604 cannot legally be sold as a supplement in Oregon or any other state.

The Gray Zone: What the Law Does Not Clearly Resolve

Several real-world questions remain genuinely unresolved as of July 2025.

Gray zone 1: Duration of the 503A evaluation period. The FDA has not published a deadline for finalizing AOD-9604's status under the 503A bulk substance evaluation. Compounding during an open evaluation is tolerated by agency practice but is not explicitly protected by statute.

Gray zone 2: Enforcement priority. The FDA has finite enforcement resources. The agency has focused recent warning letters on semaglutide, tirzepatide, and BPC-157, not specifically on AOD-9604 [6]. That does not mean AOD-9604 compounding is safe from enforcement; it means enforcement has not been the agency's visible priority in recent cycles.

Gray zone 3: Telehealth prescribing across state lines. If an Oregon patient uses a telehealth platform with a prescriber licensed in another state, the prescriber must hold an Oregon license (or qualify under applicable interstate compact provisions) for the prescription to be valid under Oregon law.

The American Academy of Family Physicians has noted that "compounded drugs are not FDA-approved and may lack the evidence base of approved drugs," a caution that applies to AOD-9604 as much as to any compounded preparation [11].

Comparison: AOD-9604 vs. Other Compounded Peptides in Oregon

| Peptide | DEA Schedule | On 503A Evaluation List | On 503B Approved List | Prescription Required | |---|---|---|---|---| | AOD-9604 | None | Under evaluation | No | Yes (503A only) | | Semaglutide (compounded) | None | Not applicable (approved drug) | Subject to shortage rules | Yes | | BPC-157 | None | Excluded (final action pending) | No | Extremely limited | | CJC-1295 | None | Under evaluation | No | Yes (503A only) | | Ipamorelin | None | Under evaluation | No | Yes (503A only) |

This table reflects the status as of July 2025. The FDA can update the 503A and 503B lists at any time; providers should verify at fda.gov/drugs/human-drug-compounding before prescribing.

What Oregon Providers Should Document

The Oregon Medical Practice Act requires that a physician's prescribing decisions be supported by a valid patient-provider relationship and a legitimate medical purpose. For AOD-9604, best practices for documentation include:

• A recorded diagnosis or clinical indication (e.g., obesity, overweight with dyslipidemia).
• Confirmation that the compounding pharmacy holds a current Oregon 503A license.
• A copy of the pharmacy's COA for the batch dispensed.
• Signed informed consent that AOD-9604 is not FDA-approved and that long-term safety data in humans is limited.
• A monitoring plan with defined follow-up intervals.

The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy note that "off-label and investigational treatments should be used only when evidence-based therapies have been inadequate and the potential benefit clearly outweighs the risk" [12]. That standard applies directly to the clinical reasoning a prescriber must document when initiating AOD-9604.